Page last updated: 2024-12-08

cinacalcet

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cinacalcet : A secondary amino compound that is (1R)-1-(naphthalen-1-yl)ethanamine in which one of the hydrogens attached to the nitrogen is substituted by a 3-[3-(trifluoromethyl)phenyl]propyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID156419
CHEMBL ID1201284
CHEBI ID48390
SCHEMBL ID71876

Synonyms (61)

Synonym
HY-70037
krn-1493
amg-073
D03504
cinacalcet (usan)
226256-56-0
CNC ,
DB01012
n-((1r)-1-(naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine
cinacalcet
(r)-alpha-methyl-n-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
(r)-n-(1-(naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine
n-[(1r)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine
CHEBI:48390 ,
NCGC00181002-03
n-[(1r)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine
NCGC00181002-02
cinacalcet [usan:inn:ban]
1-naphthalenemethanamine, alpha-methyl-n-(3-(3-(trifluoromethyl)phenyl)propyl)-, (alphar)-
n-((1r)-1-(1-naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine
uaz6v7728s ,
unii-uaz6v7728s
hsdb 7318
amg 073
amg073
krn1493
CHEMBL1201284
bdbm50416875
CS-0287
AKOS015909821
S5191
gtpl3308
1-naphthalenemethanamine, .alpha.-methyl-n-(3-(3-(trifluoromethyl)phenyl)propyl)-, (.alpha.r)-
cinacalcet [vandf]
cinacalcet [mi]
cinacalcet [usan]
cinacalcet [who-dd]
cinacalcet [inn]
n-[(1r)-1-(naphthalen-1-yl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine
cinacalcet [hsdb]
cinacalcet [ema epar]
SCHEMBL71876
(r)-n-(3-(3-trifluoromethylphenyl)propyl)-1-(1-naphthyl)ethylamine
AB01274759-01
DTXSID8048286 ,
AB01274759_02
[(1r)-1-(naphthalen-1-yl)ethyl]({3-[3-(trifluoromethyl)phenyl]propyl})amine
J-520046
AC-8974
BCP07181
BS-16242
1025064-29-2
Q193978
AMY13665
NCGC00181002-05
EN300-220098
YP4 ,
h05bx01
cinacalcetum
dtxcid3028261
(r)-alpha-methyl-n-(3-(3-(trifluoromethyl)phenyl)propyl)-1-naphthalenemethane amine

Research Excerpts

Overview

Cinacalcet is a calciomimetic drug that reproduces the action of calcium by increasing the sensitivity of the calcium-sensitive receptors (CASR) of the parathyroid glands. It can normalise calcium levels and improve the clinical condition, even in very old patients with severe PHPT who decline or are unfit for surgery.

ExcerptReferenceRelevance
"Cinacalcet is an allosteric modulator of Calciumsensing receptor (CaSR), and has been used in the treatment of these clinical entities in recent years."( Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature.
Koca, SB, 2023
)
3.07
"Cinacalcet is a calciomimetic drug that reproduces the action of calcium by increasing the sensitivity of the calcium-sensitive receptors (CASR) of the parathyroid glands that regulate the secretion of the parathyroid hormone (PTH)."( Cinacalcet treatment experience in hereditary vitamin D resistant rickets.
Badia, JL; Lucas, E; Lucas, J; Remon, A, 2020
)
2.72
"Cinacalcet is a useful and safe drug, which can normalise calcium levels and improve the clinical condition, even in very old patients with severe PHPT who decline or are unfit for surgery."( Primary Hyperparathyroidism Manifesting with Severe Hypercalcemia in a Nonagenarian Man: Pitfall of Common Imaging Techniques, Localization by 18F-Choline Positron Emission Tomography/Computed Tomography and Successful Management with Calcimimetics.
Bottoni, G; Foppiani, L; Piccardo, A, 2019
)
1.24
"Cinacalcet proved to be a safe and well tolerated drug."( Therapy for persistent hypercalcemic hyperparathyroidism post-renal transplant: cinacalcet versus parathyroidectomy.
Lima, ML; Mazzali, M; Rivelli, GG,
)
1.08
"Cinacalcet is a calcimimetic that permits impaired endothelial functions to be recovered via inhibiting parathyroid hormone (PTH) production in SHPT patients."( Effect of Cinacalcet on the Redox Status of Albumin in Secondary Hyperparathyroidism Patients Receiving Hemodialysis.
Fukagawa, M; Hirata, K; Imafuku, T; Kadowaki, D; Kato, H; Komaba, H; Maeda, H; Maruyama, T; Matsushita, K; Miyamura, S; Nakano, T; Otagiri, M; Tanaka, M; Tanaka, S; Tokunaga, K; Watanabe, H, 2020
)
1.68
"Cinacalcet is a calcimimetic that modulates the functions of calcium-sensing receptor and is currently used to treat patients with primary hyperparathyroidism (PHPT). "( Reduction in parathyroid adenomas by cinacalcet therapy in patients with primary hyperparathyroidism.
Abe, I; Kawanami, D; Kobayashi, K; Kudo, T; Minezaki, M; Mitsuoka, R; Ochi, K; Takashi, Y; Yamao, Y, 2021
)
2.34
"Cinacalcet hydrochloride is a calcimimetic agent that increases the sensitivity to the extracellular calcium of the calcium-sensing receptors of the parathyroid gland which regulates parathyroid hormone secretion. "( Cinacalcet Hydrochloride.
Al-Badr, AA; Mostafa, GAE,
)
3.02
"Cinacalcet is a calcimimetic that lowers Ca and parathyroid hormone (PTH)."( Acute effects of cinacalcet on arterial stiffness and ventricular function in hemodialysis patients: A randomized double-blinded crossover study.
Agharazii, M; Bellemare, PL; Desmeules, S; Fortier, C; Gaudreault, V; Lebel, M; Mac-Way, F; Marquis, K; Poulin, A, 2017
)
1.52
"Cinacalcet is an allosteric activator of the calcium receptor agonist, and it is used for severe hypercalcemia in patients with primary (benign and malignant) hyperparathyroidism."( Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor.
Almanza, MR; Beckers, A; Chavez, M; Daele, DV; Fernández-Ladreda, MT; Polus, M; Valdes-Socin, H,
)
1.31
"Cinacalcet is an effective treatment for renal hyperthyroidism when traditional medical therapy has failed. "( Outcomes in patients with renal hyperparathyroidism requiring cinacalcet pre-operatively followed by parathyroidectomy.
Baker, D; Callahan, RE; Czako, PF; Lloyd, LR; Nagar, S; Sevak, S, 2019
)
2.2
"Cinacalcet is a positive allosteric modulator of the calcium sensing receptor and was conditionally approved in Japan in 2014 to treat PHPT cases."( Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience.
Fujita, M; Iiri, T; Ito, N; Kinoshita, Y; Makita, N; Manaka, K; Nangaku, M; Sato, J, 2019
)
1.53
"Cinacalcet is a new effective treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients (HP), but the alterations of parathyroid gland (PTG) hyperplasia determined by cinacalcet and vitamin D have not been extensively investigated in humans."( Histology and immunohistochemistry of the parathyroid glands in renal secondary hyperparathyroidism refractory to vitamin D or cinacalcet therapy.
Bossola, M; Di Stasio, E; Fadda, G; Silvestri, P; Tazza, L; Vulpio, C, 2013
)
2.04
"Cinacalcet is a novel agent that increases sensitivity to the calcium-sensing receptor and is approved for control of UHPT."( Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients.
Chen, TC; Chiu, TT; Kuo, CC; Lee, CT; Lee, WC; Lee, YT; Ng, HY; Wu, CS, 2013
)
1.35
"Cinacalcet is a drug that acts as an allosteric activator of the calcium-sensing receptor and reduces PTH secretion."( Oral phosphorus supplementation secondarily increases circulating fibroblast growth factor 23 levels at least partially via stimulation of parathyroid hormone secretion.
Akutsu, M; Nagata, M; Takasugi, S, 2014
)
1.12
"Cinacalcet is a promising therapy widely used in dialysis patients with hyperparathyroidism resistant to conventional therapy. "( Effect of cinacalcet cessation on hyperparathyroidism in kidney transcaplant patients after long-term dialysis therapy.
Fujii, H; Fujisawa, M; Goto, S; Ishimura, T; Kono, K; Nakai, K; Nishi, S; Takeda, M; Yonekura, Y; Yoshikawa, M, 2015
)
2.26
"Cinacalcet is a calcimimetic agent licensed for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease, and for the reduction of marked hypercalcemia in patients with parathyroid carcinoma and sporadic hyperparathyroidism requiring surgery but for whom parathyroidectomy is contraindicated."( Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1).
Brandi, ML; Cianferotti, L; Cioppi, F; Colao, A; Faggiano, A; Ferolla, P; Giusti, F; Gronchi, G; Masi, L, 2016
)
2.6
"Cinacalcet hydrochloride is a new option for the treatment of SHPT, and the efficacy and effectiveness to lower parathyroid hormone levels and to improve control of mineral metabolism, even in patients with severe disease, has been well established in many clinical trials and observational studies."( Cinacalcet and Clinical Outcomes in Dialysis.
Fukagawa, M; Komaba, H,
)
2.3
"Cinacalcet is a novel, available tool to control hypercalcemia after KT."( Treatment of Persistent Hypercalcemia and Hyperparathyroidism With Cinacalcet After Successful Kidney Transplantation.
Durlik, M; Gałązka, Z; Ważna-Jabłońska, E, 2016
)
1.39
"Cinacalcet is a type II calcimimetic agent which is an allosteric modulator of the calcium-sensing receptor (CaR) located on the surface of the parathyroid cells. "( Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis.
Akinci, B; Comlekci, A; Tankurt, E, 2009
)
2.04
"Cinacalcet is a calcimimetic agent that inhibits parathyroid hormone secretion and is used to treat patients with secondary hyperparathyroidism."( Cinacalcet suppresses calcification of the aorta and heart in uremic rats.
Kawata, T; Kobayashi, N; Koyama, C; Miyata, S; Nagano, N; Obi, M; Wada, M; Wakita, S, 2008
)
2.51
"Cinacalcet is an effective treatment for secondary hyperparathyroidism in patients on dialysis. "( Mineral metabolism: Should cinacalcet be used in patients who are not on dialysis?
Cannata-Andía, JB; Fernández-Martín, JL, 2009
)
2.09
"Cinacalcet is a strong inhibitor of CYP2D6; therefore, dose adjustment of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g."( Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
Harris, R; Padhi, D, 2009
)
1.32
"Cinacalcet is an allosteric modulator of CaSR that has demonstrated safety and efficacy in controlling serum calcium values and in reducing PTH levels in patients with PHPT."( [Medical treatment of primary hyperparathyroidism: role of calcimimetics].
García Martín, A; Muñoz Torres, M, 2009
)
1.07
"Cinacalcet is an effective treatment for persistent hyperparathyroidism associated with hypercalcemia among renal transplant patients and may be helpful for hypertension control."( Treatment of persistent hyperparathyroidism in renal transplant patients with cinacalcet improves control of blood pressure.
Calvo, N; Carrasco, FR; Pérez-Flores, I; Ridao, N; Sánchez, A,
)
1.08
"Cinacalcet is an effective treatment for secondary hyperparathyroidism (SHPT) in patients with uremia on hemodialysis."( Cinacalcet in hyperfunctioning parathyroid diseases.
Imanishi, Y; Inaba, M; Kawata, T; Nishizawa, Y, 2009
)
2.52
"Cinacalcet seems to be a safe drug with no negative effect on renal function."( Treatment of hyperparathyroidism with cinacalcet in kidney transplant recipients.
Arnol, M; Borstnar, S; Erzen, B; Gmeiner Stopar, T; Kandus, A; Kocjan, T; Kovac, D, 2010
)
1.35
"Cinacalcet (CIN) is a calcimimetic drug, which contains a naphthalene chromophore and binds almost quantitatively to human serum albumin (HSA). "( Enhanced photosafety of cinacalcet upon complexation with serum albumin.
Andreu, I; Jiménez, MC; Miranda, MA; Nuin, E; Torres, MJ, 2011
)
2.12
"Cinacalcet is a calcimimetic agent, recommended for treating refractory secondary hyperparathyroidism in patients undergoing dialysis. "( [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
Blasco Mascaró, I; Mercadal Orfila, G,
)
1.82
"Cinacalcet is an effective and safe drug for controlling secondary hyperparathyroidism in dialysis, mainly when it is used in patients with baseline iPTH > 300 pg/ml."( [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
Blasco Mascaró, I; Mercadal Orfila, G,
)
1.82
"Cinacalcet, for example, is a drug that allosterically modifies the receptor so as to increase its sensitivity to circulating calcium (thus the name "calcimimetic") and in this way decreases parathyroid hormone secretion."( New insights into the role of calcium-sensing receptor activation.
Cozzolino, M; Mazzaferro, S; Messa, P,
)
0.85
"Cinacalcet is an allosteric modulator of the calcium sensing receptor acting to sensitize this receptor to the extracellular calcium. "( Update on the use of cinacalcet in the management of primary hyperparathyroidism.
Cetani, F; Marcocci, C, 2012
)
2.14
"Cinacalcet is a class II calcimimetic that increases CaSR affinity for calcium, leading to parathormone suppression and increased calcium renal excretion."( Successful use of bisphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism.
Girardin, E; Magdelaine, C; Parvex, P; Wilhelm-Bals, A, 2012
)
1.1
"Cinacalcet is an effective alternative for the treatment of hypercalcemia in patients with persistent hyperparathyroidism after KT. "( Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal.
Barros, X; Campistol, JM; Durán, CE; Paschoalin, RP; Torregrosa, JV, 2012
)
3.26
"Cinacalcet is an effective treatment for hypercalcemia due to persistent hyperparathyroidism (HPT) in patients who have undergone kidney transplantation (KT). "( Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up.
Barros, X; Campistol, JM; Durán, CE; Paschoalin, RP; Sánchez-Escuredo, A; Torregrosa, JV, 2012
)
3.26
"Cinacalcet hydrochloride is a calcimimetic agent indicated for the treatment of secondary hyperparathyroidism in dialysis-dependent patients with chronic kidney disease. "( Micromethod for quantification of cinacalcet in human plasma by liquid chromatography-tandem mass spectrometry using a stable isotope-labeled internal standard.
Barco, S; Cangemi, G; Della Casa Alberighi, O; Melioli, G; Scurati, S; Verrina, EE, 2013
)
2.11
"Cinacalcet HCl (AMG 073) is an investigational oral calcimimetic drug currently being evaluated for the treatment of primary and secondary hyperparathyroidism (HPT). "( Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism.
Franceschini, N; Joy, MS; Kshirsagar, A, 2003
)
3.2
"Cinacalcet is a calcimimetic agent that is now available for use clinically to manage secondary hyperparathyroidism among patients undergoing dialysis regularly. "( Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?
Goodman, WG, 2005
)
1.77
"Cinacalcet is a new drug with antiparathyroid effects that belongs to the class of calcimimetics. "( [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].
Mosekilde, L; Nielsen, LR; Vestergaard, P, 2006
)
2.69
"Cinacalcet (CNC) is a CaM endowed with the unique prerogative to significantly decrease serum PTH while also decreasing serum calcium."( Therapy of secondary hyperparathyroidism to date: vitamin D analogs, calcimimetics or both?
Cannella, G; Messa, P,
)
0.85
"Cinacalcet HCl is a new calcimimetic that has been used successfully for the treatment of primary and secondary hyperparathyroidism in adults, but its use in adolescents has not been reported."( Persistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl.
Bruns, DE; D'Amour, P; Hanks, JB; Henrich, LM; Levine, MA; Rogol, AD, 2006
)
1.27
"Cinacalcet is a type II calcimimetic approved for treatment of secondary hyperparathyroidism in patients with end-stage renal disease. "( Cinacalcet-induced hungry bone syndrome.
Lazar, ES; Stankus, N,
)
3.02
"Cinacalcet appears to be an effective drug for the treatment of posttransplant hypercalcemia due to persistent secondary hyperparathyroidism. "( Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation.
Cincotta, E; Doshi, MD; El-Amm, JM; Gruber, SA; Losanoff, JE; Migdal, S; Morawski, K; Singh, A; Sternbauer, D; West, MS, 2007
)
2.08
"Cinacalcet is a calcimimtic agent used to treat secondary hyperparathyroidism in patients with end-stage renal disease on dialysis or hypercalcemia related to parathyroid carcinoma. "( Cinacalcet-associated cardiogenic shock in a patient with cardiomyopathy.
Colin Forfar, J; Tilling, L, 2007
)
3.23
"Cinacalcet is a calcimimetic drug that has been approved for treatment of secondary and tertiary hyperparathyroidism in patients with renal failure requiring renal replacement therapy. "( Decrease in serum tacrolimus level and rise in serum creatinine under late addition of cinacalcet in a renal transplant recipient with hyperparathyroidism: a case report.
Heller, T; Koziolek, MJ; Maass, E; Mueller, GA, 2007
)
2.01
"Cinacalcet is a calcimimetic drug for the treatment of secondary hyperparathyroidism (HPT). "( Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation.
Braun, SC; Corti, N; Hersberger, M; Russmann, S; Savoca, R; Serra, AL; Starke, A; Wüthrich, RP, 2008
)
2.05
"Cinacalcet hydrochloride is a calcimimetic agent that activates the calcium-sensing receptor on the surface of parathyroid cells and inhibits parathyroid hormone (PTH) secretion. "( Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akiba, T; Akizawa, T; Iwasaki, M; Koshikawa, S; Tsukamoto, Y; Uchida, E, 2008
)
2.1

Effects

Cinacalcet hydrochloride has been used successfully in U.S., Europe, and Japan in the treatment of SHPT. The drug has nonlinear PK properties over a dose range of 25 to 100 mg after a single dose.

ExcerptReferenceRelevance
"Cinacalcet has a unique mechanism for reducing PTH concentration and appears to be a safe and effective oral therapy for both primary and secondary HPT."( Calcimimetics and the treatment of primary and secondary hyperparathyroidism.
Franceschini, N; Joy, MS; Kshirsagar, AV, 2004
)
1.77
"Cinacalcet has been demonstrated to be effective in inhibiting PTH secretion, though the drug fails to normalize PTH release, both in PHPT and SHPT patients with different degrees of disease severity, including patients with parathyroid carcinomas and with MEN1-related parathyroid tumors."( Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors.
Corbetta, S; Mingione, A; Soldati, L; Terranegra, A; Verdelli, C, 2015
)
1.37
"Cinacalcet has been well tolerated by 28 patients, whereas five individuals complained of heartburn and grade 1 nausea, which did not prevent the completion of the study."( Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1).
Brandi, ML; Cianferotti, L; Cioppi, F; Colao, A; Faggiano, A; Ferolla, P; Giusti, F; Gronchi, G; Masi, L, 2016
)
2.6
"Cinacalcet has proved effective to control secondary hyperparathyroidism in patients on haemodialysis (HD). "( Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability.
Duarte-Gallego, V; Esteve Simo, V; Fulquet Nicolas, M; Macias-Toro, J; Martínez Calvo, G; Moreno-Guzmán, F; Pou Potau, M; Ramírez-de Arellano Serna, M; Saurina Sole, A, 2015
)
1.86
"Cinacalcet has nonlinear PK properties over a dose range of 25 to 100 mg after a single dose."( Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study.
Chen, X; Gao, F; Hu, P; Jiang, J; Liu, H; Liu, T; Wang, H, 2016
)
1.41
"Cinacalcet has nonlinear PK properties over a dose range of 25 to 100 mg after a single dose."( Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study.
Chen, X; Gao, F; Hu, P; Jiang, J; Liu, H; Liu, T; Wang, H, 2016
)
1.41
"Cinacalcet hydrochloride has been used successfully in U.S., Europe, and Japan in the treatment of SHPT, while maintaining serum levels of calcium and phosphorus."( Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis.
Chen, N; Ding, X; Hou, F; Jiang, G; Li, X; Liu, H; Mei, C; Qian, J; Wang, L; Wang, M; Wang, N; Yu, X; Zuo, L, 2016
)
1.47
"Cinacalcet has previously been shown to reduce hypercalcaemia in patients with primary HPT."( Successful treatment of recurrent renal stones with Cinacalcet in a patient with primary hyperparathyroidism.
Chauhan, P; Geberhiwot, T; Gittoes, NJ, 2016
)
1.41
"Cinacalcet has recently been approved by Federal Drug Administration (FDA) for the treatment of patients with secondary hyperparathyroidism on maintenance dialysis and hypercalcemia in patients with parathyroid cancer."( Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis.
Akinci, B; Comlekci, A; Tankurt, E, 2009
)
1.32
"Cinacalcet has been associated with improved pain control and ulcer healing."( Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis.
Raymond, CB; Wazny, LD, 2008
)
1.33
"Cinacalcet has improved the management of hyperparathiroidism (HPTH) in hemodialysis. "( [Cinacalcet in patients on peritoneal dialysis with moderate to severe hyperparathyroidism resistant to conventional treatment, a one-year, prospective study].
Cava, F; Gruss, E; López-Sánchez, P; Molano, MD; Ortigosa, A; Portolés, J; Tato, A, 2008
)
2.7
"Cinacalcet has been well tolerated, we reduced the dose in a single patient due to secondary effects, but treatment was not discontinued in any case."( [Cinacalcet in patients on peritoneal dialysis with moderate to severe hyperparathyroidism resistant to conventional treatment, a one-year, prospective study].
Cava, F; Gruss, E; López-Sánchez, P; Molano, MD; Ortigosa, A; Portolés, J; Tato, A, 2008
)
1.98
"Cinacalcet has no significant interaction with calcium carbonate or sevelamer hydrochloride, phosphate binders commonly used in the treatment of patients with CKD receiving dialysis."( Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
Harris, R; Padhi, D, 2009
)
1.32
"Cinacalcet has been shown to decrease serum calcium and parathyroid hormone serum levels in patients with PHPT."( Cinacalcet for the treatment of primary hyperparathyroidism.
Dillon, ML; Frazee, LA, 2011
)
2.53
"Cinacalcet has recently been introduced as a treatment for secondary hyperparathyroidism in dialysis patients and for parathyroid carcinoma. "( Clinical utilization of cinacalcet in hypercalcemic conditions.
Alfieri, C; Brezzi, B; Messa, P, 2011
)
2.12
"Cinacalcet has proved efficient in short- and long-term controls of hypercalcemia and, though bone mineral density was not improved, the available data point to cinacalcet as the treatment of choice in non-operable patients with pHPT."( Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.
Duntas, LH; Stathatos, N, 2011
)
2.53
"Cinacalcet (Sensipar) has been shown to decrease calcium levels in patients with primary hyperparathyroidism (PHPT); however, few other endpoints have been studied and long-term effects are not known."( Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.
Lopez, J; Norman, J; Politz, D, 2012
)
3.26
"Cinacalcet has been shown to be effective in lowering serum intact parathyroid hormone (iPTH) levels in patients with advanced secondary hyperparathyroidism (SHPT). "( Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism.
Kinugasa, E; Koiwa, F; Kumata-Maeta, C; Mizobuchi, M; Ogata, H; Shishido, K; Yamamoto, M; Yoshida, N, 2012
)
2.06
"Cinacalcet has been shown to be effective in reducing or normalizing serum calcium levels in several groups of patients with primary hyperparathyroidism (PHPT), including patients with mild to moderate PHPT, intractable PHPT, and parathyroid carcinoma, and in PHPT as a part of multiple endocrine neoplasia type 1."( Update on the use of cinacalcet in the management of primary hyperparathyroidism.
Cetani, F; Marcocci, C, 2012
)
1.42
"Cinacalcet has been used in controlling secondary hyperparathyroidism (SHPT) in dialysis patients since 2004, but its full economic evaluation has not been conducted from the US perspective. "( Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States.
Belozeroff, V; Boer, R; Lalla, AM, 2012
)
2.14
"Cinacalcet has been used to control hypercalcemia in KT patients."( Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal.
Barros, X; Campistol, JM; Durán, CE; Paschoalin, RP; Torregrosa, JV, 2012
)
2.54
"Cinacalcet HCl has demonstrated efficacy in controlling the hypercalcaemia of severe primary HPT and in reducing parathyroid hormone levels in patients with secondary HPT."( Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism.
Franceschini, N; Joy, MS; Kshirsagar, A, 2003
)
2.48
"Cinacalcet has a unique mechanism for reducing PTH concentration and appears to be a safe and effective oral therapy for both primary and secondary HPT."( Calcimimetics and the treatment of primary and secondary hyperparathyroidism.
Franceschini, N; Joy, MS; Kshirsagar, AV, 2004
)
1.77
"Cinacalcet has also reduced serum calcium levels in patients with primary HPT, including parathyroid carcinoma, in the clinical trial setting."( Cinacalcet HCl: a novel therapeutic for hyperparathyroidism.
de Francisco, AL, 2005
)
2.49
"Cinacalcet hydrochrolide has now become available in Japan after a three-year interval from its introduction to Western countries. "( [Basic and clinical aspects of calcimimetics. Calcimimetics from the viewpoint of medical cost].
Hamano, T, 2008
)
1.79

Actions

ExcerptReferenceRelevance
"Cinacalcet can also suppress PTH secretion due to parathyroid carcinoma in the same way as it does for parathyroid hyperplasia in the uremic condition."( The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case report.
Fuse, M; Kada, S; Takada, D; Tsukamoto, T; Yanagita, M, 2017
)
1.57

Treatment

Cinacalcet-treated subjects were more likely to achieve a mean iPTH

ExcerptReferenceRelevance
"Cinacalcet-treated patients experienced more cardiovascular-related hospitalizations than those who underwent PTx (P = .008) but the difference became insignificant after adjusting for baseline difference in heart failure (P = .43)."( Parathyroidectomy versus oral cinacalcet on cardiovascular parameters in peritoneal dialysis patients with advanced secondary hyperparathyroidism (PROCEED): a randomized trial.
Cheung, SC; Lang, BH; Lo, WK; Tang, TK; Wang, AY; Yau, YY, 2023
)
1.92
"Cinacalcet treatment was initiated on the 2nd DoL with the diagnosis of NSHPT due to hypocalciuric hypercalcemia and elevated PTH level."( Cinacalcet as a First-Line Treatment in Neonatal Severe Hyperparathyroidism Secondary to Calcium Sensing Receptor (CaSR) Mutation.
Ata, P; Bereket, A; Bilgen, H; Eltan, M; Gulcan-Kersin, S; Kirkgoz, T; Ozek, E; Rzayev, T; Turan, S, 2020
)
2.72
"Cinacalcet treatment leads to a significant increase in parathyroid oxyphil cell content but paricalcitol does not, reinforcing a role for the calcium-sensing receptor activation in the transdifferentiation of chief-to-oxyphil cell type."( Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
Brown, AJ; Coyne, DW; Gupta, D; Miller, B; Ritter, C; Slatopolsky, E; Zheng, S, 2017
)
1.52
"The cinacalcet treatment cohort (CT) demonstrated a greater duration of renal replacement therapy (p = 0.03) relative to the untreated cohort (NC)."( Outcomes in patients with renal hyperparathyroidism requiring cinacalcet pre-operatively followed by parathyroidectomy.
Baker, D; Callahan, RE; Czako, PF; Lloyd, LR; Nagar, S; Sevak, S, 2019
)
1.24
"Cinacalcet treatment was independently associated with the reduction of FGF23 in our PD patients."( Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study.
Ahn, C; Chang, JH; Hwang, YH; Kim, D; Kim, H; Kim, HJ; Kim, YL; Kim, YS; Lee, J; Na, KY; Oh, KH; Shin, N; Song, YR, 2013
)
3.28
"3. Cinacalcet treatment was well tolerated and caused only a few side effects."( Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
Adamczak, M; Kuczera, P; Więcek, A, 2013
)
1.17
"1. Cinacalcet treatment decreases plasma FGF23 concentration in haemodialysed patients with secondary hyperparathyroidism. "( Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
Adamczak, M; Kuczera, P; Wiecek, A, 2014
)
2.47
"Cinacalcet treatment was initiated at a median of 20 months after RT (median dose 30 mg/day)."( Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study.
Bravo, J; Crespo, J; Díaz, JM; García, MR; Gentil, MÁ; Gómez Alamillo, C; Gómez, G; Gutiérrez Dalmau, A; Jiménez, VL; Jimeno, L; Morales, E; Rodríguez Benot, A; Romero, R; Sáez, MJ; Torregrosa, JV, 2014
)
2.57
"Cinacalcet treatment (10 mg/kg) in the same model resulted in acutely lowered plasma PTH levels which returned to placebo levels by 24 hours post-dose."( Comparison of AMG 416 and cinacalcet in rodent models of uremia.
Alexander, ST; Baruch, A; Dong, J; Janes, J; Johnson, RM; Karim, F; Maclean, D; Mendel, DB; Sho, E; Walter, S; Yin, Q, 2014
)
1.42
"Cinacalcet treatment was associated with an increase in rate of hungry bones (P = .04)."( The effect of cinacalcet on intraoperative findings in tertiary hyperparathyroidism patients undergoing parathyroidectomy.
Chen, H; Schneider, DF; Sippel, RS; Somnay, YR; Weinlander, E, 2014
)
1.48
"Cinacalcet treatment for six months resulted in a significant reduction in the serum phosphate and iPTH levels while the serum calcium levels remained unchanged."( Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients.
Aamer, MA; Bashir, SO; Morsy, MD; Omer, HA; Somialy, R, 2015
)
1.38
"Cinacalcet treatment increased the rate of hypocalcemia (RR 6.0, 95% CI 3.65-9.87; heterogeneity: p= 0.71, I(2)= 0%, absolute effect 20 more per 1000 [95% CI 11 more to 36 more], high quality of evidence)."( Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis.
Agarwal, A; Busse, JW; Guyatt, GH; Lopes, LC; Mustafa, RA; Sekercioglu, MF; Sekercioglu, N; Shaikh, S; Thabane, L, 2016
)
2.6
"Cinacalcet-treated HepG2 cells in the presence of oleic acid exhibited a19% increased TG content."( Calcium sensing receptor effects in adipocytes and liver cells: Implications for an adipose-hepatic crosstalk.
Arreguin, A; Arrese, M; Cifuentes, M; D'Espessailles, A; Fuentes, C; Mattar, P; Reyes, M; Villarroel, P, 2016
)
1.16
"The cinacalcet treatment group consisted of eight hemodialysis patients with secondary hyperparathyroidism who received cinacalcet for 7-14 months."( Change in coronary artery calcification score due to cinacalcet hydrochloride administration.
Fujii, M; Maeda, K; Mizutani, R; Myochin, H; Narita, M; Ohbayashi, T; Tsuruta, Y, 2008
)
1.08
"Cinacalcet treatment also efficaciously reduced elevated serum calcium and phosphorus levels."( Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.
Fukagawa, M; Komaba, H, 2008
)
1.47
"Cinacalcet treatment tended toward a decreased percentage of patients with AP >or=120 U/L (baseline, 42.6%; week 52, 30.6%) compared with control (35.0 to 48.6%, respectively)."( Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients.
Belozeroff, V; Goodman, WG; Kalantar-Zadeh, K; Ren, L, 2009
)
2.52
"Cinacalcet treatment followed by parathyroid surgery reduced serum calcium concentration."( [Patient with chronic kidney disease and primary or tertiary hyperparathyroidism--case report].
Błazejewska, A; Flisiński, M; Manitius, J; Pypkowski, J, 2009
)
1.07
"Cinacalcet treatment in patients with secondary hyperparathyroidism significantly reduced the total parathyroid gland volume in a short 6-month period. "( Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.
Chou, H; Ichii, M; Inaba, M; Ishimura, E; Kato, Y; Maekawa, K; Nagasue, K; Nishizawa, Y; Okuno, S; Tsuboniwa, N; Yamakawa, T, 2010
)
2.06
"In cinacalcet treatment of hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT), not only intact parathyroid hormone (I-PTH), whole PTH (W-PTH), and bone markers, but also W-PTH/I-PTH ratio as proportion of active PTH(1-84) molecules were decreased. "( Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism.
Imanishi, Y; Inaba, M; Ishimura, E; Kurajoh, M; Nagayama, H; Nishizawa, Y; Okuno, S; Shoji, S; Yamada, S; Yamakawa, T, 2011
)
1.22
"Cinacalcet treatment was associated with a decline of renal function in kidney transplant recipients with persistent HPT. "( Renal function in patients treated with cinacalcet for persistent hyperparathyroidism after kidney transplantation.
Bischoff-Ferrari, HA; Henschkowski, J; Serra, AL; Wüthrich, RP, 2011
)
2.08
"Cinacalcet treatment for secondary hyperparathyroidism (SHPT) has demonstrated parathyroid size regression and morphological changes, such as cystic degeneration and hypovascularisation, on ultrasonography. "( Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride.
Inoshita, N; Marui, Y; Nakamura, M; Ohashi, K; Sumida, K; Takaichi, K; Tanaka, K; Tomikawa, S; Ubara, Y, 2011
)
2.02
"Cinacalcet treatment of sHPT results in reduction of FGF-23 levels, probably due to the suppression of osteoblasts function."( Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism.
Brzosko, S; Hryszko, T; Koc-Zorawska, E; Mysliwiec, M; Rydzewska-Rosolowska, A, 2012
)
3.26
"Cinacalcet based treatment facilitates achievement of the K/DOQI targets for iPTH and bone mineral metabolism compared with conventional therapy in hemodialysis patients."( Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
Alsahow, AE; Alsaran, K; Atia, M; El-Shafey, EM; Sabry, AA, 2011
)
2.53
"Cinacalcet treatment is cost-effective for treatment of SHPT in the US. "( Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States.
Belozeroff, V; Boer, R; Lalla, AM, 2012
)
2.14
" Cinacalcet treatment does not affect the markers of endothelial function and selected adipokines. "( Effect of secondary hyperparathyroidism treatment with cinacalcet on selected adipokines and markers of endothelial injury in hemodialysis patients: a preliminary report.
Brzosko, S; Hryszko, T; Koc-Żórawska, E; Myśliwiec, M; Naumnik, B; Rydzewska-Rosołowska, A, 2012
)
1.54
"Cinacalcet HCl treatment also simultaneously lowered serum calcium and phosphorus, and calcium-phosphorous product levels."( Cinacalcet hydrochloride.
Barman Balfour, JA; Scott, LJ, 2005
)
2.49
"Cinacalcet-treated subjects were more likely to achieve a mean iPTH ( Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.
Block, GA; Chertow, GM; Coburn, JW; Cunningham, J; Drüeke, TB; Goodman, WG; Martin, KJ; McCary, LC; Moe, SM; Olson, KA; Quarles, LD; Sherrard, DJ; Turner, SA, 2005
)
2
"Cinacalcet treatment enables a significant number of patients to achieve the K/DOQI guideline."( Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
Ito, H; Kinugasa, E; Koiwa, F; Ogata, H, 2006
)
1.06
"Cinacalcet treatment resulted in increased renal phosphate reabsorption, allowed for a decrease in phosphate supplementation, and showed evidence of bone healing in one of the two patients."( Cinacalcet in the management of tumor-induced osteomalacia.
Adams, JS; Collins, MT; Geller, JL; Kelly, MH; Khosravi, A; Riminucci, M, 2007
)
2.5
"Cinacalcet treatment induced a significant 14.3 +/- 12.1% decrease in Tac AUC(0-12) (P = 0.039). "( Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
Asberg, A; Bergan, S; Falck, P; Holdaas, H; Midtvedt, K; Reubsaet, JL; Vethe, NT, 2008
)
3.23
"Cinacalcet treatment showed a moderate effect on the Tac, but not CsA or mycophenolate, pharmacokinetics after 1-week concomitant treatment. "( Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
Asberg, A; Bergan, S; Falck, P; Holdaas, H; Midtvedt, K; Reubsaet, JL; Vethe, NT, 2008
)
3.23
"Cinacalcet treatment was the only predictor of this ratio."( Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?
Basile, C; Bruno, A; Cazzato, F; Chimienti, D; Cocola, S; Lomonte, C; Teutonico, A; Vernaglione, L, 2008
)
1.07
"Cinacalcet treatment decreased PTH and diminished activation frequency, bone formation rate/bone surface, and fibrosis surface/bone surface."( An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.
Baker, N; Charytan, C; Coburn, JW; Coyne, DW; Frazã O, JM; Goodman, WG; Kaplan, MR; Malluche, HH; McCary, LC; Monier-Faugere, MC; Turner, SA; Wang, G, 2008
)
1.41
"Cinacalcet treatment also led to a decrease in the set point for Ca(2+) and to a leftward shift of the Ca(2+)-PTH curve."( Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet.
Amado, JA; Arias, M; Cunningham, J; de Francisco, AL; Fresnedo, GF; Izquierdo, M; Palomar, R; Piñera, C; Unzueta, MG, 2008
)
1.28
"Treatment with cinacalcet was initiated at a median of 25 months after renal transplant."( Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
Fyssa, L; Goumenos, DS; Ntrinias, T; Papachristou, E; Papasotiriou, M; Savvidaki, E; Zavvos, V, 2018
)
1.16
"Treatment with cinacalcet began a median of 16 months after RT (median dose of 30 mg/day)."( [Cinacalcet in the management of normocalcaemic secondary hyperparathyroidism after kidney transplantation: one-year follow-up multicentre study].
Bravo, J; Crespo, J; Díaz, JM; Gentil, MA; Gómez, G; Gómez-Alamillo, C; Gutiérrez-Dalmau, Á; Jimeno, L; López-Jiménez, V; Morales, E; Pérez-Sáez, MJ; Rodríguez-Benot, A; Rodríguez-García, M; Romero, R; Torregrosa, JV, 2014
)
1.65
"Treatment with cinacalcet significantly lowers serum FGF23. "( Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Block, GA; Chertow, GM; Correa-Rotter, R; Dehmel, B; Drüeke, TB; Floege, J; Goodman, WG; Herzog, CA; Kubo, Y; London, GM; Mahaffey, KW; Moe, SM; Parfrey, PS; Stolina, M; Wheeler, DC, 2015
)
2.21
"Treatment with cinacalcet decreases serum total and free testosterone concentration in male hemodialysed patients with chronic kidney disease and secondary hyperparathyroidism."( Changes of Serum Total and Free Testosterone Concentrations in Male Chronic Hemodialysis Patients with Secondary Hyperparathyroidism in Response to Cinacalcet Treatment.
Adamczak, M; Kuczera, P; Wiecek, A, 2016
)
0.99
"Treatment with cinacalcet resulted in a significant decrease in serum calcium level (mean, 9.9 ± 0.7 mg/dL; P < .001), a reduction in intact parathyroid hormone level (308 ± 199 pg/dL; P < .001), and an increase in phosphorus concentration (mean, 2.8 ± 0.6 mg/dL; P < .001)."( Treatment of Persistent Hypercalcemia and Hyperparathyroidism With Cinacalcet After Successful Kidney Transplantation.
Durlik, M; Gałązka, Z; Ważna-Jabłońska, E, 2016
)
1.01
"Treatment with cinacalcet was initiated at 30 mg/day and adjusted to achieve National Kidney Foundation Kidney Disease Outcomes Quality Initiative targets for iPTH, P, Ca and Ca-P product."( Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients.
Aladrén Regidor, MJ, 2009
)
2.14
"Treatment with cinacalcet controlled hyperparathyroidism and hypercalcemia among patients with posttransplant SHP. "( Treatment with cinacalcet of secondary hyperparathyroidism after renal transplantation.
Alarcón Zurita, A; Gómez Marqués, G; Losada González, P; Molina Guasch, M; Munar Vila, MA; Obrador Mulet, A; Pascual Felip, MJ; Uriol Rivera, M; Vilar Gimeno, A,
)
0.84
"Treatment with cinacalcet effectively reduced levels of calcium (baseline, 11.1 +/- 0.8 vs 9.7 +/- 0.6 mg/dL at 12 months; P < .05) and intact parathyroid hormone (iPTH; baseline, 288 +/- 155 vs 236 +/- 118 pg/mL at 12 months; P = NS). "( Treatment with cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism.
Burgos, D; Cabello, M; González Molina, M; Gutiérrez, C; Hernández, D; López, V; Rodríguez, MA; Sola, E; Sujan, S; Toledo, R,
)
0.84
"Treatment with cinacalcet resulted in correction of calcium and phosphorus concentrations (10.1 [0.4] mg/dL and 1.7 [0.7] mg/dL, respectively)."( Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.
Bergua, C; Campistol, JM; Martinez de Osaba, MJ; Oppenheimer, F; Torregrosa, JV,
)
0.69
"Treatment with cinacalcet and intravenous bisphosphonate has improved the previously often fatal prognosis of parathyroid cancer. "( [Management of serum calcium with cinacelet in parathyroid cancer].
Sanden, AK; Vestergaard, P, 2009
)
0.71
"Treatment with Cinacalcet plus low-dose calcitriol analogs results in lower FGF23 levels compared with a treatment regimen using calcitriol analogs alone in ESRD. "( Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.
Krebill, R; Liu, S; Menard, R; Quarles, LD; Wetmore, JB, 2010
)
1.1
"Treatment with cinacalcet effectively decreased intact PTH by 55% from baseline in group S and by 58% in group L."( Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.
Fujimori, A; Fukagawa, M; Hasegawa, H; Komaba, H; Kurosawa, T; Nakanishi, S; Nishioka, M; Shibuya, K; Shin, J; Tanaka, M, 2010
)
2.14
"Treatment with cinacalcet resulted in normocalcaemia and a strong improvement of symptoms."( Therapeutic challenges in elderly patients with symptomatic hypercalcaemia caused by primary hyperparathyroidism.
Jacobs, L; Koek, HL; Samson, MM; Verhaar, HJ, 2012
)
0.72
"SHPT treatment with cinacalcet decreased calcium, phosphate, and intact parathormone (iPTH) levels; however, no significant changes in sTM, E-selectin, leptin, or adiponectin were observed."( Effect of secondary hyperparathyroidism treatment with cinacalcet on selected adipokines and markers of endothelial injury in hemodialysis patients: a preliminary report.
Brzosko, S; Hryszko, T; Koc-Żórawska, E; Myśliwiec, M; Naumnik, B; Rydzewska-Rosołowska, A, 2012
)
0.94
"Treatment with cinacalcet improves the control of secondary hyperparathyroidism (SHPT) and the achievement of calcium and phosphorus targets. "( Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
Bridges, I; Christiano, C; Cooper, K; Cournoyer, SH; Covic, A; Farouk, M; Kopyt, NP; Rodriguez, M; Ureña-Torres, P; Zehnder, D, 2013
)
1.12
"Treatment with cinacalcet in clinical trials has safely and effectively improved achievement of the NKF-K/DOQI goals."( Cinacalcet HCl: a novel therapeutic for hyperparathyroidism.
de Francisco, AL, 2005
)
2.11
"Treatment with cinacalcet HCl was initiated and a pharmacodynamic profile was obtained for serum calcium, phosphorus, and PTH."( Persistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl.
Bruns, DE; D'Amour, P; Hanks, JB; Henrich, LM; Levine, MA; Rogol, AD, 2006
)
0.89
"Treatment with cinacalcet resulted in increased renal phosphate reabsorption and serum phosphorus and allowed for a decrease in phosphate supplementation to a dose that was tolerated."( Cinacalcet in the management of tumor-induced osteomalacia.
Adams, JS; Collins, MT; Geller, JL; Kelly, MH; Khosravi, A; Riminucci, M, 2007
)
2.12
"Treatment with cinacalcet is a safe and effective therapy for long-term control of secondary hyperparathyroidism. "( Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism.
Arruda, JA; Bahner, U; Block, GA; Corpier, C; Disney, A; Klassen, PS; Olson, KA; Schwanauer, LE; Soroka, SD; Sterrett, JR; Strom, J; Stummvoll, HK, 2007
)
2.14
"Treatment with cinacalcet resulted in a 61% decline in intact PTH (iPTH) levels (1,070 +/- 171.5 pretreatment to 417.6 +/- 97.8 posttreatment pg/ml, p = 0.005)."( Cinacalcet is efficacious in pediatric dialysis patients.
Kher, KK; Khurana, M; Moudgil, A; Moylan, K; Silverstein, DM; Wilcox, J, 2008
)
2.13
"The treatment with cinacalcet was generally well tolerated in this study."( Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akiba, T; Akizawa, T; Iwasaki, M; Koshikawa, S; Tsukamoto, Y; Uchida, E, 2008
)
0.98
"Treatment with cinacalcet lowered PTH and reduced bone turnover and tissue fibrosis among most dialysis patients with biochemical evidence of sHPT."( An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.
Baker, N; Charytan, C; Coburn, JW; Coyne, DW; Frazã O, JM; Goodman, WG; Kaplan, MR; Malluche, HH; McCary, LC; Monier-Faugere, MC; Turner, SA; Wang, G, 2008
)
1.04

Toxicity

Cinacalcet is an effective and safe drug for controlling secondary hyperparathyroidism in dialysis, mainly when it is used in patients with baseline iPTH > 300 pg/ml. The most common adverse events from cinacAlcet treatment were gastrointestinal symptom, such as nausea and appetite loss.

ExcerptReferenceRelevance
" Cinacalcet HCl was reasonably tolerated, and the incidence of adverse events was similar between groups (76%, cinacalcet; 80%, placebo)."( Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily.
Harris, RZ; Marbury, TC; Noveck, RJ; Padhi, D; Salfi, M; Sullivan, JT, 2004
)
1.49
" The incidence of adverse events was similar between groups."( Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily.
Harris, RZ; Marbury, TC; Noveck, RJ; Padhi, D; Salfi, M; Sullivan, JT, 2004
)
0.58
" Treatment generally was well tolerated, and most adverse events were mild to moderate in severity."( A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Abboud, HE; Albizem, MB; Block, GA; Charytan, C; Chonchol, M; de Francisco, AL; Jolly, S; Kaplan, M; Kubo, Y; Locatelli, F; Mix, TC; Roger, SD; Sarkar, S, 2009
)
0.57
"Cinacalcet is an effective and safe drug for controlling secondary hyperparathyroidism in dialysis, mainly when it is used in patients with baseline iPTH > 300 pg/ml."( [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
Blasco Mascaró, I; Mercadal Orfila, G,
)
1.82
"Calcimimetic treatment effectively improved biochemical parameters of SHPT patients receiving dialysis without increasing all-cause mortality and all adverse events."( Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis.
Chen, J; Gu, Y; Hao, C; Li, H; Li, M; Ni, L; You, L; Zhang, Q, 2012
)
0.38
" During the treatment any presence of cinacalcet side effect and its intensity was noted."( [The influence of side effects related to cinacalcet therapy on compliance in hemodialysis patients suffering from secondary hyperparathyroidism].
Chrul, S; Zwiech, R, 2012
)
0.91
"The incidence of cinacalcet adverse events was regarded as the factor which had an insignificant influence on patients'adherence to this medication."( [The influence of side effects related to cinacalcet therapy on compliance in hemodialysis patients suffering from secondary hyperparathyroidism].
Chrul, S; Zwiech, R, 2012
)
0.98
" Cholecalciferol substitution was well tolerated without adverse effects."( Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency.
Lhotta, K; Mündle, M; Sprenger-Mähr, H; Zitt, E, 2015
)
0.42
" Adverse events and serious adverse events were recorded, and causal analysis performed."( Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis.
Chen, N; Ding, X; Hou, F; Jiang, G; Li, X; Liu, H; Mei, C; Qian, J; Wang, L; Wang, M; Wang, N; Yu, X; Zuo, L, 2016
)
0.74
"This study aimed to investigate the association of gastrointestinal (GI) adverse events of cinacalcet with gallstones in the hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT)."( Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.
Ohno, Y; Oshima, J; Otsuka, K, 2018
)
0.93
" Regarding its safety, no upper gastrointestinal adverse event occurred after the single and multiple administration of evocalcet at doses up to 12 mg."( Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.
Akizawa, T; Fukagawa, M; Shimazaki, R; Shiramoto, M, 2018
)
0.48
" Overall, 82% of patients on cinacalcet and 86% on placebo had ≥ 1 treatment-emergent adverse event; the most common were vomiting (32%, 24%, respectively), hypocalcemia (23%, 19%), nausea (18%, 14%), and hypertension (14%, 24%)."( A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
Ariceta, G; Dehmel, B; Hidalgo, G; Iles, JN; Jiang, X; Laskin, B; Schaefer, F; Shahinfar, S; Vande Walle, J; Warady, BA, 2019
)
1.03
" The most common adverse events from cinacalcet treatment were gastrointestinal symptom, such as nausea and appetite loss."( Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience.
Fujita, M; Iiri, T; Ito, N; Kinoshita, Y; Makita, N; Manaka, K; Nangaku, M; Sato, J, 2019
)
1.08
" Demographic, laboratory data and adverse events were assessed."( Safety and Efficacy of a 3-Year Therapy With Cinacalcet in Persistent Hyperparathyroidism After Renal Transplant.
Lopes de Lima, M; Mazzali, M; Rivelli, GG, 2020
)
0.82
"Cinacalcet therapy proved to be efficient for PPTHP and safe for graft and patient."( Safety and Efficacy of a 3-Year Therapy With Cinacalcet in Persistent Hyperparathyroidism After Renal Transplant.
Lopes de Lima, M; Mazzali, M; Rivelli, GG, 2020
)
2.26
" Cinacalcet and vitamin D may have a small or no increase in overall adverse events."( The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Bakaa, L; Bilezikian, JP; Brandi, ML; Chang, Y; Clarke, B; Couban, RJ; Guyatt, G; Khan, AA; Manja, V; Mannstadt, M; Silverberg, SJ; Sreekanta, A; Tangamornsuksun, W; Tong, K; Wang, Y; Ye, Z; Zhang, M; Zhang, Y, 2022
)
1.63

Pharmacokinetics

The pharmacokinetic parameters of cinacalcet were not affected by co-administration of CaCO(3), sevelamer HCl or pantoprazole. There was no evidence of increasing exposure with increasing degree of renal impairment.

ExcerptReferenceRelevance
" This report describes the salient pharmacodynamic properties, using several test systems, of a new calcimimetic compound, cinacalcet HCl."( Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl.
Balandrin, MF; Colloton, M; Fox, J; Harris, R; Heaton, WH; Karbon, W; Lacey, D; Martin, D; Miller, M; Nemeth, EF; Qi, M; Rishton, G; Scherrer, J; Scully, S; Shatzen, E; Van Wagenen, BC, 2004
)
0.78
" Noncompartmental methods were used to analyze the pharmacokinetic parameters of cinacalcet (the free-base)."( Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily.
Harris, RZ; Marbury, TC; Noveck, RJ; Padhi, D; Salfi, M; Sullivan, JT, 2004
)
0.8
"Following single-dose administration of cinacalcet, there was no evidence of increasing exposure with increasing degree of renal impairment, and the pharmacokinetic profile was similar for all subjects regardless of whether they were receiving haemodialysis (no difference on dialysis or nondialysis days detected) or peritoneal dialysis."( No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara).
Harris, RZ; Padhi, D; Salfi, M; Sullivan, JT, 2005
)
0.84
" Additionally, the pharmacokinetic profiles of R- or S-warfarin were similar for all subjects."( Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin.
Padhi, D; Sullivan, JT, 2007
)
1.78
" Blood samples were obtained predose and up to 72 hours postdose for pharmacokinetic (AUCinfinity, Cmax) and safety evaluations."( The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals.
Harris, RZ; Padhi, D; Salfi, M,
)
0.44
" Pharmacokinetic parameters were analysed using a crossover ANOVA model that included subjects who completed both treatment arms."( Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole.
Harris, RZ; Padhi, D; Salfi, M; Sullivan, JT, 2007
)
0.66
" Twelve-hour pharmacokinetic investigations to measure CsA and its six main metabolites, Tac and mycophenolate concentrations were performed before and after 1-week treatment with 30 mg cinacalcet once daily."( Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
Asberg, A; Bergan, S; Falck, P; Holdaas, H; Midtvedt, K; Reubsaet, JL; Vethe, NT, 2008
)
1.98
" Blood samples were taken for pharmacokinetic (pre-dose and up to 120 hours post-dose) and pharmacodynamic (pre-dose and up to 72 hours post-dose) evaluations."( Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
Harris, RZ; Noveck, RJ; Padhi, D; Salfi, M; Sullivan, JT, 2008
)
0.61
" The terminal elimination half-life is 30-40 hours, and steady-state concentrations are achieved within 7 days."( Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
Harris, R; Padhi, D, 2009
)
0.6
"The aim of this study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) properties and tolerability of single-dose cinacalcet 50 to 100 mg in healthy male Korean subjects for the purposes of a New Drug Application package for the Korean Food and Drug Administration."( Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study.
Gu, N; Jang, IJ; Kim, BH; Lee, S; Lim, KS; Shin, SG; Yu, KS, 2012
)
0.82
" Saliva and plasma samples were collected for 3-5 half-life values of sitagliptin, cinacalcet, metformin, montelukast, tolterodine, hydrochlorothiazide (HCT), lornoxicam, azithromycin, diacerhein, rosuvastatin, cloxacillin, losartan and tamsulosin after oral dosing."( Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system.
Arafat, T; Idkaidek, N, 2012
)
0.6
"Cinacalcet induces immediate changes in serum PTH levels, but the pharmacodynamic effect throughout the daily dosing interval in controlled patients is unknown."( Pharmacodynamics of cinacalcet over 48 hours in patients with controlled secondary hyperparathyroidism: useful data in clinical practice.
Almadén, Y; Arenas, MD; de la Fuente, V; Delgado, P; Gil, MT; Gutiérrez, P; Ribero, J; Rodríguez, M, 2013
)
2.16
"Three randomized, open-label, two-way crossover pharmacokinetic studies were conducted in healthy subjects."( Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet.
Harris, R; Padhi, D; Sullivan, JT, 2014
)
0.62
"The pharmacokinetic parameters of cinacalcet were not affected by co-administration of CaCO(3), sevelamer HCl or pantoprazole."( Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet.
Harris, R; Padhi, D; Sullivan, JT, 2014
)
0.9
"The aim of this study was to assess the pharmacokinetic (PK) and pharmacodynamic (PD) properties and safety of single and multiple doses of cinacalcet in Chinese healthy volunteers (HVs) for the purposes of a New Drug Application package for the Chinese Food and Drug Administration."( Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study.
Chen, X; Gao, F; Hu, P; Jiang, J; Liu, H; Liu, T; Wang, H, 2016
)
0.89
"5-2 h (median), and the elimination half-life was 12."( Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.
Akizawa, T; Fukagawa, M; Shimazaki, R; Shiramoto, M, 2018
)
0.48
"The aims of this study were to develop a pharmacokinetic (PK) and PK-pharmacodynamic (PK/PD) model of cinacalcet in adults and paediatrics with secondary hyperparathyroidism (SHPT) on dialysis, to test covariates of interest, and to perform simulations to inform dosing in paediatrics with SHPT."( Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic-pharmacodynamic analysis of cinacalcet.
Chen, P; Gisleskog, PO; Melhem, M; Narayanan, A; Sohn, W, 2019
)
0.93
"Here, we present a linear multi-compartment model based on physiological principles such as first-pass metabolism and protein binding, which captures all relevant pharmacokinetic parameters of cinacalcet."( A Multi-Compartment Model Capturing the Pharmacokinetics of the Calcimimetic Cinacalcet.
Fuertinger, DH; Kotanko, P; Schappacher-Tilp, G, 2019
)
0.93
"In most drug development settings, the regulatory approval process is accompanied by extensive studies performed to understand the drug's pharmacokinetic (PK) and pharmacodynamic (PD) properties."( Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidism.
Al-Kofahi, M; Basu, C; Brundage, R; Carlin, BP; Ma, X; Mo, M; Xia, HA, 2020
)
0.56
" DC-PTH has a half-life of 11."( Development of a Hypoparathyroid Male Rodent Model for Testing Delayed-Clearance PTH Molecules.
Eastell, R; Esfahani, SHZ; Newell-Price, J; Ramezanipour, N; Ross, RJ; Trevitt, G; Wilkinson, IR, 2022
)
0.72
" This work describes the development and verification of physiologically-based pharmacokinetic (PBPK) models for the CYP2D6-sensitive substrate, nebivolol and the index CYP2D6 inhibitors, mirabegron and cinacalcet."( Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug-Drug Interactions.
Gardner, I; Khoshaein, N; Kilford, P; Southall, R, 2022
)
1.13
"The exposure of nebivolol, cinacalcet and mirabegron predicted by the PBPK models was verified against pharmacokinetic data from 13, 3 and 9 clinical studies, respectively."( Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug-Drug Interactions.
Gardner, I; Khoshaein, N; Kilford, P; Southall, R, 2022
)
1.24

Compound-Compound Interactions

Cinacalcet combined with low dose calcitriol can improve high calcium, high phosphorus, and high iPTH in MHD patients with severe SHPT.

ExcerptReferenceRelevance
"8-fold] when administered with ketoconazole, relative to when administered alone."( Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole.
Harris, RZ; Padhi, D; Salfi, M; Sullivan, JT, 2007
)
0.66
" The aim of the SENSOR study was to demonstrate that cinacalcet given in a more clinically practical manner with the first major meal after dialysis is noninferior to cinacalcet given with food during the dialysis session."( Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study.
Asensio, C; Bover, J; Carter, D; Dellanna, F; Gross, P; Jehle, PM; Sánchez González, MC; Sanz, D; Schaefer, RM; Zani, V, 2008
)
0.97
"Cinacalcet combined with vitamin D analogues was no more effective than vitamin D analogues in achieving the primary ACHIEVE end point and incurred greater costs."( Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Almehmi, A; Lu, J; Pregenzer, M; Quarles, LD; Shireman, TI; Wetmore, JB, 2010
)
2.12
" In this study, the efficacy of cinacalcet in combination with alendronate has been retrospectively evaluated in patients with PHPT."( Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.
Colao, A; Coppola, A; Di Somma, C; Faggiano, A; Gasperi, M; Lombardi, G; Panico, F; Ramundo, V; Savastano, S; Severino, R; Vuolo, L, 2011
)
2.1
" Randomized controlled trials on cinacalcet combined with vitamin D and/or phosphate binders in the dialysis patients with SHPT were identified in Pubmed, Sciencedirect, and the Cochrane library."( The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
Jiang, W; Li, D; Shao, L; Xu, Y; Zhang, W; Zhou, H, 2013
)
1.02
"
 Methods: Thirty SHPT patients were enrolled to receive treatment of cinacalcet combined with low-dose calcitriol, with inclusion criteria as follows: maintenance on MHD>6 months; serum intact parathyroid hormone (iPTH)>600 pg/mL; parathyroid glands with more than 1 nodules by ultrasonography; traditional therapy with no effects."( [Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism].
Chen, X; Liu, H; Wang, C; Yuan, F; Zhou, A, 2017
)
1.08
"To observe the clinical outcome and the effect of bone metabolism of cinacalcet combined with calcitriol in maintenance hemodialysis (MHD) patients with severe secondary hyperparathyroidism (SHPT)."( Effect of Cinacalcet Combined with Calcitriol on the Clinical Outcome and Bone Metabolism in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism.
Chen, X; Li, Z; Liu, H; Wang, C; Yuan, F, 2018
)
1.12
"Cinacalcet combined with low dose calcitriol can improve high calcium, high phosphorus, and high iPTH in MHD patients with severe SHPT and also improve bone metabolism."( Effect of Cinacalcet Combined with Calcitriol on the Clinical Outcome and Bone Metabolism in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism.
Chen, X; Li, Z; Liu, H; Wang, C; Yuan, F, 2018
)
2.33
" The performance of the PBPK models was verified by comparing the simulated results against reported human systemic exposure and clinical drug-drug interactions (DDIs) studies."( Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug-Drug Interactions.
Gardner, I; Khoshaein, N; Kilford, P; Southall, R, 2022
)
0.94

Bioavailability

The aim of the study was to improve the bioavailability of Cinacalcet hydrochloride (CLC) and enhance its efficacy by the nanoemulsion drug delivery system. The pharmacological effects of evocalcet were observed at lower doses because of its higher bioavailability than cinacAlcet, which may have contributed to the reduced GI tract symptoms.

ExcerptReferenceRelevance
" In vivo studies in rats demonstrated cinacalcet HCl is orally bioavailable and displays approximately linear pharmacokinetics over the dose range of 1 to 36 mg/kg."( Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl.
Balandrin, MF; Colloton, M; Fox, J; Harris, R; Heaton, WH; Karbon, W; Lacey, D; Martin, D; Miller, M; Nemeth, EF; Qi, M; Rishton, G; Scherrer, J; Scully, S; Shatzen, E; Van Wagenen, BC, 2004
)
0.84
" In all species examined, cinacalcet was well absorbed, with greater than 74% oral bioavailability of cinacalcet-derived radioactivity in monkeys and humans."( Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models.
Ghoborah, H; Gohdes, M; Kumar, GN; Padhi, D; Poppe, L; Roskos, L; Sproul, C; Turner, S, 2004
)
0.88
" plant derived), and the protein-to-phosphorus ratio in the bioavailability of phosphorus from food."( Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
Adema, AY; de Borst, MH; Ter Wee, PM; Vervloet, MG, 2014
)
0.4
" Plant-phosphorus (legumes and nuts), mainly associated with InsP6, is less absorbable by the human gastrointestinal tract as the bioavailability of phosphorous from plant-derived foods is very low."( Plant phosphates, phytate and pathological calcifications in chronic kidney disease.
Buades Fuster, JM; Grases Freixedas, F; Perelló Bestard, J; Sanchís Cortés, P,
)
0.13
"The present research indicated that a new self-microemulsifying drug delivery systems (SMEDDS) were used to reduce the food effect of poorly water-soluble drug cinacalcet and enhance the bioavailability in beagle dogs by oral gavage."( Formulation optimization and pharmacokinetics evaluation of oral self-microemulsifying drug delivery system for poorly water soluble drug cinacalcet and no food effect.
Cao, M; Chen, G; Liu, L; Pei, X; Qian, Y; Ren, L; Xue, X, 2018
)
0.88
" The pharmacological effects of evocalcet were observed at lower doses because of its higher bioavailability than cinacalcet, which may have contributed to the reduced GI tract symptoms."( A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.
Akizawa, T; Fukagawa, M; Haruyama, W; Hisada, Y; Kawata, T; Masuda, N; Miyazaki, H; Murai, M; Shoukei, Y; Tokunaga, S; Wada, M; Yanagida, T, 2018
)
0.69
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The aim of the study was to improve the bioavailability of Cinacalcet hydrochloride (CLC) and enhance its efficacy by the nanoemulsion drug delivery system."( Cinacalcet hydrochloride-nanoemulsion: preparation, characterization, enhanced bioavailability and pharmacodynamics.
Chen, GG; Ren, LL; Wang, J, 2022
)
2.41
" The release of CLC-NE in vitro was investigated with four different dissolution media, and the bioavailability of CLC-NE in vivo was studied through beagle dogs."( Cinacalcet hydrochloride-nanoemulsion: preparation, characterization, enhanced bioavailability and pharmacodynamics.
Chen, GG; Ren, LL; Wang, J, 2022
)
2.16
" CLC-NE has similar dissolution rates in different pH media, and the relative bioavailability of CLC-NE was 166."( Cinacalcet hydrochloride-nanoemulsion: preparation, characterization, enhanced bioavailability and pharmacodynamics.
Chen, GG; Ren, LL; Wang, J, 2022
)
2.16

Dosage Studied

Cinacalcet induces immediate changes in serum PTH levels, but the pharmacodynamic effect throughout the daily dosing interval in controlled patients is unknown. A regimen of intravenous paricalcitol was more cost effective than cinacAlcet plus low-dose vitamin D in the management of iPTH in patients with SHPT requiring haemodialysis.

ExcerptRelevanceReference
" Maximum decreases in PTH of over 50% occurred 2-4 h after dosing in all cinacalcet-treated groups."( The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.
Bilezikian, JP; Guo, MD; McCary, LC; Peacock, M; Shoback, DM; Turner, SA, 2003
)
0.89
" Median oral clearance ranged from 222 to 599 L/h, and median time after dosing when C max occurred ranged from 2 to 3 hours across all doses."( Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily.
Harris, RZ; Marbury, TC; Noveck, RJ; Padhi, D; Salfi, M; Sullivan, JT, 2004
)
0.58
" Cinacalcet HCl, dosed from 30 to 180 mg/day, significantly reduced PTH while simultaneously lowering calcium, phosphorus, and calcium-phosphorus product in each of the three studies."( Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres, PU, 2006
)
2.69
" Uremic patients, however, suffer from severe deprivation of biological vitamin D effects, that puts them in need of highly dosed vitamin D in order to both ameliorate their bone status and to preserve their general and cardiovascular health."( Therapy of secondary hyperparathyroidism to date: vitamin D analogs, calcimimetics or both?
Cannella, G; Messa, P,
)
0.13
" the time of initiation of cinacalcet after transplantation, its dosage and the side effects on kidney function all remain unknown."( Hypercalciuria induced by a high dose of cinacalcet in a renal-transplant recipient.
Durand, D; Esposito, L; Gennero, I; Kamar, N; Mehrenberger, M; Rostaing, L, 2007
)
0.9
"001), and allowed a 22% reduction in vitamin D dosage in patients receiving vitamin D at baseline."( The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
Bos, WJ; Bouman, K; Braun, J; Brink, H; Carter, D; Frazão, JM; Graf, H; Locatelli, F; Macário, F; Maduell, F; Messa, P; Molemans, B; Reichel, H; Saha, H; Torregrosa, V; von Albertini, B; Wilkie, M; Yaqoob, M; Zani, VJ, 2008
)
0.63
" The use of CBPBs was classified as "consistent" or "inconsistent" with the guidelines 1 month after the blood tests of May 2006 (to allow time for dosing adjustments)."( Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.
Covit, A; Pepe, J; Shastri, J; Sherman, RA; Tran, A, 2008
)
0.35
" The safety and optimal dosage of the drug in hypercalcemic patients with liver impairment remains unclear."( Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis.
Akinci, B; Comlekci, A; Tankurt, E, 2009
)
0.6
" For investigation of this hypothesis, nine long-term hemodialysis patients with secondary hyperparathyroidism were given cinacalcet for 2 mo, the dosage was titrated per a protocol based on intact PTH and plasma calcium concentrations."( Cinacalcet reduces the set point of the PTH-calcium curve.
Aljama, P; Almaden, Y; Cañadillas, S; Martin-Malo, A; Rodriguez, M; Rodriguez, ME; Santamaría, R; Valle, C, 2008
)
2
" Further research is necessary to fully describe the optimal use of sodium thiosulfate, bisphosphonates, and cinacalcet for the treatment of calciphylaxis, including their pharmacokinetics in adults with CKD, optimal dosing strategies, and duration of therapy."( Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis.
Raymond, CB; Wazny, LD, 2008
)
0.82
" Blood samples were collected predose and at selected time points up to 24 hours after dosing with midazolam for measurement of midazolam pharmacokinetic parameters."( Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
Emery, M; Padhi, D; Salfi, M, 2008
)
1.79
" We aimed to characterize adult patients who received cinacalcet prescriptions and to determine (1) dosage titration and effects on laboratory values, active intravenous vitamin D use, and phosphate binder prescriptions and (2) percentage who achieved National Kidney Foundation Kidney Disease Outcomes Quality Initiative targets for serum parathyroid hormone, calcium, and phosphorus and experienced biochemical adverse effects."( Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006.
Arko, C; Block, GA; Li, Q; Liu, J; Nieman, K; Persky, M; St Peter, WL, 2009
)
2.04
" Over 12 mo, vitamin D use and use consistency increased, phosphate binder dosages increased, and mean cinacalcet daily dosage reached 55 mg."( Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006.
Arko, C; Block, GA; Li, Q; Liu, J; Nieman, K; Persky, M; St Peter, WL, 2009
)
2.01
" Positive effects were less dramatic than in Phase III clinical trials, possibly as a result of modest, slow dosage titration."( Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006.
Arko, C; Block, GA; Li, Q; Liu, J; Nieman, K; Persky, M; St Peter, WL, 2009
)
1.8
" The findings showed that cinacalcet reduced serum PTH, Ca, and Pi levels and that if the patient had lower PTH levels at baseline, the dosage of vitamin D could be greatly reduced."( Does cinacalcet improve the prognosis of dialysis patients?
Fujimi, S; Hirakata, H; Iida, M; Taniguchi, M; Tokumoto, M; Tsuruya, K; Yamada, S, 2009
)
1.17
"The ADVANCE (A Randomized Study to Evaluate the Effects of Cinacalcet plus Low-Dose Vitamin D on Vascular Calcification in Subjects with Chronic Kidney Disease Receiving Haemodialysis) Study objective is to assess the effect of cinacalcet plus low-dose active vitamin D versus flexible dosing of active vitamin D on progression of coronary artery calcification (CAC) in haemodialysis patients."( Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients.
Block, GA; Chertow, GM; Csiky, B; Dehmel, B; Downey, G; Floege, J; Goodman, WG; Lopez, N; Moustafa, M; Naso, A; Nossuli, K; Raggi, P; Torres, PU, 2010
)
0.83
" Adult haemodialysis patients with moderate to severe secondary hyperparathyroidism (intact parathyroid hormone [iPTH] >300 pg/mL or bio-intact PTH >160 pg/mL) and baseline CAC score >or=30 were stratified by CAC score (>or=30-399, >or=400-999, >or=1000) and randomized in a 1:1 ratio to cinacalcet (30-180 mg/day) plus low-dose active vitamin D (cinacalcet group) or flexible dosing of active vitamin D alone (control)."( Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients.
Block, GA; Chertow, GM; Csiky, B; Dehmel, B; Downey, G; Floege, J; Goodman, WG; Lopez, N; Moustafa, M; Naso, A; Nossuli, K; Raggi, P; Torres, PU, 2010
)
0.76
"4% patients who were prescribed a mean final CC dosage of 51+/-30 mg/day."( [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].
Chazot, C; Deleaval, P; Hurot, JM; Jean, G; Lorriaux, C; Mayor, B; Terrat, JC; Vanel, T; Vovan, C, 2010
)
0.57
" The aim of the study was to evaluate the efficacy of cinacalcet on the achievement of targets in the treatment of hyperparathyroidism in two different dosage schedules."( A novel dose regimen of cinacalcet in the treatment of severe hyperparathyroidism in hemodialysis patients.
Al-Azmi, M; Al-Hilali, N; Hussain, N; Kawy, YA, 2011
)
0.92
" In the study, alteration of vitamin D dosage was not permitted except for the case in which serum calcium could not be managed by calcium carbonate adjustment alone."( Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
Fujimori, A; Fukagawa, M; Koizumi, M; Komaba, H; Nakanishi, S, 2012
)
1.82
" Medical treatment with cinacalcet is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on darbepoetin dosing is unknown."( Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.
Bargman, JM; Battistella, M; Chan, CT; Richardson, RM, 2011
)
0.94
" Patients received 6 months of compassionate treatment with cinacalcet, which was initiated at a dose of 30 mg/day orally and flexibly dosed thereafter based on iPTH levels."( Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.
Cornago, I; Gallardo, I; García-Ledesma, P; Hernando, A; Martinez, I; Montenegro, J; Muñoz, RI; Romero, MA, 2012
)
0.93
" Cinacalcet dosage required to normalize calcium in MEN1 and sPHPT was not significantly different (45±21 vs 54±25 mg/day)."( MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.
Beck-Peccoz, P; Corbetta, S; Eller-Vainicher, C; Ermetici, F; Filopanti, M; Olgiati, L; Persani, L; Spada, A; Verga, U, 2012
)
1.55
" Prescription patterns were defined based on cinacalcet administration (starting or not) and VDRA dosage change (decreased [<-25%], stable [-25% to 25%], or increased [>25%])."( Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study.
Akizawa, T; Fukagawa, M; Fukuhara, S; Fukuma, S; Hasegawa, T; Kurokawa, K; Onishi, Y; Yamaguchi, T, 2012
)
0.88
" The percentage of patients in whom there was a 30% decrease in serum iPTH levels by the end of the dosing was higher in cinacalcet group than that in control group(OR = 10."( Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis.
Chen, J; Gu, Y; Hao, C; Li, H; Li, M; Ni, L; You, L; Zhang, Q, 2012
)
0.59
"Cinacalcet induces immediate changes in serum PTH levels, but the pharmacodynamic effect throughout the daily dosing interval in controlled patients is unknown."( Pharmacodynamics of cinacalcet over 48 hours in patients with controlled secondary hyperparathyroidism: useful data in clinical practice.
Almadén, Y; Arenas, MD; de la Fuente, V; Delgado, P; Gil, MT; Gutiérrez, P; Ribero, J; Rodríguez, M, 2013
)
2.16
" To enhance compliance, we evaluated effectiveness of post-dialysis dosing of cinacalcet (group AD) as compared to daily home administration (group D) in a prospective randomized trial of HD patients with refractory SHPT."( A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet.
Abbachi, F; Abouchacra, S; Bernsen, R; Chaaban, A; Gebran, N; Haq, N; Hassan, M; Khan, I, 2014
)
0.86
"Although daily dosing overall was more effective for treatment of SHPT, dialysis dosing was effective in patients with less severe SHPT."( A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet.
Abbachi, F; Abouchacra, S; Bernsen, R; Chaaban, A; Gebran, N; Haq, N; Hassan, M; Khan, I, 2014
)
0.63
" The dosing of study drugs and phosphate binders in the IMPACT study may not reflect actual practice, and patients were followed for 28 weeks, while the treatment of SHPT is long-term."( Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Ketteler, M; Khan, SS; Marshall, TS; Schumock, GT; Sharma, A, 2013
)
0.61
" Although many recent case reports have shown exceptional results and healing with the use of sodium thiosulphate, we did not experience any change in the poor prognosis of our patients with the use of this drug, at a dosage of 5 g thrice weekly endovenously."( Calciphylaxis in dialysis patients, a severe disease poorly responding to therapies: report of 4 cases.
Aldi, M; Cantelli, S; Gaddoni, G; Misciali, C; Odorici, G; Patrizi, A; Savoia, F; Tampieri, E; Tampieri, G, 2013
)
0.39
" However, upon longer-term (10 day) exposure to the adipogenic cocktail, cinacalcet exerted the opposite effect, causing a dose-response increase in the expression of the mature adipose markers adipocyte protein 2, adiponectin, peroxisome proliferator-activated receptor γ, fatty acid synthase, and glycerol-3-phosphate dehydrogenase."( Adipogenic effect of calcium sensing receptor activation.
Ben-Jonathan, N; Cifuentes, M; Fuentes, C; Hugo, E; Martínez, J; Reyes, M; Segovia, MP; Tobar, N; Villalobos, E; Villarroel, P, 2013
)
0.62
" Costs were estimated by examining the dosage of the study drug (paricalcitol or cinacalcet) and phosphate binders used by each participant during the trial."( Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Johns, B; Khan, SS; Marshall, TS; Sharma, A, 2014
)
0.89
"On the basis of dosing and effectiveness data from US patients in the IMPACT SHPT study, we found that a regimen of intravenous paricalcitol was more cost effective than cinacalcet plus low-dose vitamin D in the management of iPTH in patients with SHPT requiring haemodialysis."( Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Johns, B; Khan, SS; Marshall, TS; Sharma, A, 2014
)
0.86
"05 for both dosing strata) at Weeks 8, 16 and 28."( Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Cozzolino, M; Goldsmith, D; Ketteler, M; Khan, S; Martin, KJ; Sharma, A, 2014
)
0.74
" Both studies included a control (vehicle) group and a comparison cinacalcet group (po dosing at 30 mg/kg and 10 mg/kg for the 1K1C and 5/6 Nx studies, respectively)."( Comparison of AMG 416 and cinacalcet in rodent models of uremia.
Alexander, ST; Baruch, A; Dong, J; Janes, J; Johnson, RM; Karim, F; Maclean, D; Mendel, DB; Sho, E; Walter, S; Yin, Q, 2014
)
0.94
" In the 5/6 Nx chronic uremia model, daily IV dosing of AMG 416 over 4 weeks (1 mg/kg) resulted in a sustained reduction in PTH, with approximately 50% of the initial level observed 48 hours post treatment throughout the study."( Comparison of AMG 416 and cinacalcet in rodent models of uremia.
Alexander, ST; Baruch, A; Dong, J; Janes, J; Johnson, RM; Karim, F; Maclean, D; Mendel, DB; Sho, E; Walter, S; Yin, Q, 2014
)
0.7
"For patients with PHPT, aged 23-92 years, starting cinacalcet treatment for the first time, information was collected on dosing pattern, biochemistry and adverse drug reactions (ADRs)."( The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice.
Body, JJ; Cáp, J; Farouk, M; Gessl, A; Hofbauer, LC; Kuhn, JM; Marcocci, C; Mattin, C; Muñoz Torres, M; Payer, J; Schwarz, P; Selby, P; Van De Ven, A; Yavropoulou, M, 2014
)
0.88
"It is necessary to show that the active content in the dosage form of drugs is within a certain narrow range of the label claim."( Application of (19)  F time-domain NMR to measure content in fluorine-containing drug products.
Cobas, C; Iglesias, I; Kook, AM; Li, L; Nagapudi, K; Peng, C; Silva Elipe, MV, 2016
)
0.43
" The dosage of cinacalcet was optimized for each patient in order to obtain a reduction of parathyroid hormone (PTH) within normal limits while enabling the maintenance of adequate calcemic values."( Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study.
Brardi, S; Cevenini, G; Ponchietti, R; Romano, G; Verdacchi, T, 2015
)
1.23
" Whether substitution of native vitamin D in these patients is beneficial is a matter of ongoing discussion, as is the optimal dosing schedule."( Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency.
Lhotta, K; Mündle, M; Sprenger-Mähr, H; Zitt, E, 2015
)
0.42
"The dosing regimen of oral cholecalciferol supplementation with 100 IU per kg body weight per week for 26 weeks in dialysis patients with vitamin D deficiency causes a significant increase in 25OHD3 close to the supposed target level of 30 ng/mL and a significant reduction in iPTH, without affecting serum calcium or phosphorous levels."( Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency.
Lhotta, K; Mündle, M; Sprenger-Mähr, H; Zitt, E, 2015
)
0.42
"3 mg/dL) at the end of the titration phase with cinacalcet at a dosage of up to 75 mg three times a day."( Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism.
Katagiri, M; Miura, D; Nakashima, N; Ohishi, H; Shimazaki, R; Takahashi, S; Takeuchi, Y; Tominaga, Y, 2017
)
2.15
"3 mg/dL or less, the patient reached the highest possible dosage of 90 mg four times daily, or the patient experienced an adverse event that precluded further dosage increases."( Cinacalcet as symptomatic treatment of hypercalcaemia in primary hyperparathyroidism prior to surgery.
Misiorowski, W; Zgliczyński, W, 2017
)
1.9
" Therefore, screening for gallstones before dosing cinacalcet may reduce the risk of GI adverse events in SHPT patients."( Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.
Ohno, Y; Oshima, J; Otsuka, K, 2018
)
0.97
" Our objectives were to determine a safe and effective dosing regimen of cinacalcet in the treatment of infants and young children with sHPT that was refractory to standard care and to examine their growth during treatment."( Cinacalcet as rescue therapy for refractory hyperparathyroidism in young children with advanced chronic kidney disease.
Abitbol, CL; Arenas Morales, AJ; Chandar, J; DeFreitas, MJ; Freundlich, M; Katsoufis, CP; Seeherunvong, W; Zilleruelo, G, 2019
)
2.19
"Cinacalcet may be used effectively and safely in infants and small children with refractory sHPT in advanced CKD using a cautious dosing regimen."( Cinacalcet as rescue therapy for refractory hyperparathyroidism in young children with advanced chronic kidney disease.
Abitbol, CL; Arenas Morales, AJ; Chandar, J; DeFreitas, MJ; Freundlich, M; Katsoufis, CP; Seeherunvong, W; Zilleruelo, G, 2019
)
3.4
" The dose-response profile for each evocalcet group vs placebo showed statistically significant differences for all contrast patterns."( Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study.
Akizawa, T; Fukagawa, M; Shimazaki, R, 2018
)
0.48
"The aims of this study were to develop a pharmacokinetic (PK) and PK-pharmacodynamic (PK/PD) model of cinacalcet in adults and paediatrics with secondary hyperparathyroidism (SHPT) on dialysis, to test covariates of interest, and to perform simulations to inform dosing in paediatrics with SHPT."( Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic-pharmacodynamic analysis of cinacalcet.
Chen, P; Gisleskog, PO; Melhem, M; Narayanan, A; Sohn, W, 2019
)
0.93
" We conclude that, except for optimal dosage of elementary phosphate and alphacalcidol, cinacalcet prior to parathyroidectomy may be an effective option in patients with HR complicated with THP."( Successful management of tertiary hyperparathyroidism associated with hypophosphataemic rickets in an adult.
Anagnostis, P; Tournis, S; Vamvakidis, K, 2019
)
0.74
" Since the patient declined surgery, and zoledronate was unfit owing to areas of rarefaction of the jaw, the calcimimetic cinacalcet was started; the dosage was progressively titrated up to 120 mg/day with normalisation of calcium levels over time."( Primary Hyperparathyroidism Manifesting with Severe Hypercalcemia in a Nonagenarian Man: Pitfall of Common Imaging Techniques, Localization by 18F-Choline Positron Emission Tomography/Computed Tomography and Successful Management with Calcimimetics.
Bottoni, G; Foppiani, L; Piccardo, A, 2019
)
0.72
" The study objectives were to assess the control of PTH, Ca, and Phos over time in patients receiving cinacalcet or etelcalcetide as well as dosing and time to discontinuation for etelcalcetide."( Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients.
Belozeroff, V; Chonchol, M; Danese, MD; Desai, P; Gleeson, M; Lin, TC; Lubeck, D; Martin, K, 2020
)
0.77
" Animals were then dosed with either single or repeated subcutaneous doses of PTH 1-34 or a DC-PTH at 20 nmol/kg."( Development of a Hypoparathyroid Male Rodent Model for Testing Delayed-Clearance PTH Molecules.
Eastell, R; Esfahani, SHZ; Newell-Price, J; Ramezanipour, N; Ross, RJ; Trevitt, G; Wilkinson, IR, 2022
)
0.72
"The dosage of evocalcet required to control serum parathyroid hormone (PTH) levels varies among secondary hyperparathyroidism (SHPT) patients."( Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism.
Akizawa, T; Asada, S; Endo, Y; Fukagawa, M; Kurita, N; Tokumoto, M; Tokunaga, S, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
calcimimeticA drug that it mimics the action of calcium on tissues.
P450 inhibitorAn enzyme inhibitor that interferes with the activity of cytochrome P450 involved in catalysis of organic substances.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
naphthalenesAny benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
(trifluoromethyl)benzenesAn organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency51.48050.141337.9142100.0000AID1490; AID2701
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID504865
PPM1D proteinHomo sapiens (human)Potency29.41070.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency11.90470.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
PINK1Homo sapiens (human)Potency44.66842.818418.895944.6684AID624263
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.37910.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency10.06830.001310.157742.8575AID1259253; AID1259256
GVesicular stomatitis virusPotency26.83700.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency0.01900.00108.379861.1304AID1645840
67.9K proteinVaccinia virusPotency17.78280.00018.4406100.0000AID720580
ParkinHomo sapiens (human)Potency44.66840.819914.830644.6684AID624263
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.25890.035520.977089.1251AID504332
huntingtin isoform 2Homo sapiens (human)Potency15.84890.000618.41981,122.0200AID1688
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency25.66510.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency16.51080.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency14.38180.005612.367736.1254AID624032
Interferon betaHomo sapiens (human)Potency28.76730.00339.158239.8107AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency26.83700.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency26.83700.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency26.83700.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Angiotensin-converting enzyme 2 Homo sapiens (human)IC50 (µMol)28.20000.00042.207910.0000AID1808024
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glycine receptor subunit alpha-1Homo sapiens (human)EC50 (µMol)0.32000.32001.45774.2000AID1203550
Extracellular calcium-sensing receptorHomo sapiens (human)EC50 (µMol)0.08000.02000.23341.0000AID738057
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (126)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
startle responseGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
startle responseGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processGlycine receptor subunit alpha-1Homo sapiens (human)
monoatomic ion transportGlycine receptor subunit alpha-1Homo sapiens (human)
chloride transportGlycine receptor subunit alpha-1Homo sapiens (human)
muscle contractionGlycine receptor subunit alpha-1Homo sapiens (human)
neuropeptide signaling pathwayGlycine receptor subunit alpha-1Homo sapiens (human)
acrosome reactionGlycine receptor subunit alpha-1Homo sapiens (human)
visual perceptionGlycine receptor subunit alpha-1Homo sapiens (human)
adult walking behaviorGlycine receptor subunit alpha-1Homo sapiens (human)
neuronal action potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neuromuscular process controlling postureGlycine receptor subunit alpha-1Homo sapiens (human)
negative regulation of transmission of nerve impulseGlycine receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, glycinergicGlycine receptor subunit alpha-1Homo sapiens (human)
righting reflexGlycine receptor subunit alpha-1Homo sapiens (human)
excitatory postsynaptic potentialGlycine receptor subunit alpha-1Homo sapiens (human)
inhibitory postsynaptic potentialGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to amino acid stimulusGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to zinc ionGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to ethanolGlycine receptor subunit alpha-1Homo sapiens (human)
response to alcoholGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of presynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGlycine receptor subunit alpha-1Homo sapiens (human)
positive regulation of acrosome reactionGlycine receptor subunit alpha-1Homo sapiens (human)
chemical synaptic transmissionGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
ossificationExtracellular calcium-sensing receptorHomo sapiens (human)
response to ischemiaExtracellular calcium-sensing receptorHomo sapiens (human)
detection of calcium ionExtracellular calcium-sensing receptorHomo sapiens (human)
intracellular calcium ion homeostasisExtracellular calcium-sensing receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayExtracellular calcium-sensing receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayExtracellular calcium-sensing receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayExtracellular calcium-sensing receptorHomo sapiens (human)
JNK cascadeExtracellular calcium-sensing receptorHomo sapiens (human)
chemosensory behaviorExtracellular calcium-sensing receptorHomo sapiens (human)
positive regulation of cell population proliferationExtracellular calcium-sensing receptorHomo sapiens (human)
anatomical structure morphogenesisExtracellular calcium-sensing receptorHomo sapiens (human)
positive regulation of gene expressionExtracellular calcium-sensing receptorHomo sapiens (human)
positive regulation of insulin secretionExtracellular calcium-sensing receptorHomo sapiens (human)
bile acid secretionExtracellular calcium-sensing receptorHomo sapiens (human)
cellular response to hepatocyte growth factor stimulusExtracellular calcium-sensing receptorHomo sapiens (human)
vasodilationExtracellular calcium-sensing receptorHomo sapiens (human)
positive regulation of vasoconstrictionExtracellular calcium-sensing receptorHomo sapiens (human)
branching morphogenesis of an epithelial tubeExtracellular calcium-sensing receptorHomo sapiens (human)
positive regulation of positive chemotaxisExtracellular calcium-sensing receptorHomo sapiens (human)
fat pad developmentExtracellular calcium-sensing receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeExtracellular calcium-sensing receptorHomo sapiens (human)
calcium ion importExtracellular calcium-sensing receptorHomo sapiens (human)
cellular response to vitamin DExtracellular calcium-sensing receptorHomo sapiens (human)
cellular response to glucose stimulusExtracellular calcium-sensing receptorHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusExtracellular calcium-sensing receptorHomo sapiens (human)
cellular response to hypoxiaExtracellular calcium-sensing receptorHomo sapiens (human)
response to fibroblast growth factorExtracellular calcium-sensing receptorHomo sapiens (human)
positive regulation of calcium ion importExtracellular calcium-sensing receptorHomo sapiens (human)
cellular response to peptideExtracellular calcium-sensing receptorHomo sapiens (human)
chloride transmembrane transportExtracellular calcium-sensing receptorHomo sapiens (human)
regulation of calcium ion transportExtracellular calcium-sensing receptorHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (43)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transmembrane signaling receptor activityGlycine receptor subunit alpha-1Homo sapiens (human)
protein bindingGlycine receptor subunit alpha-1Homo sapiens (human)
zinc ion bindingGlycine receptor subunit alpha-1Homo sapiens (human)
glycine bindingGlycine receptor subunit alpha-1Homo sapiens (human)
extracellularly glycine-gated chloride channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
taurine bindingGlycine receptor subunit alpha-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neurotransmitter receptor activityGlycine receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
phosphatidylinositol phospholipase C activityExtracellular calcium-sensing receptorHomo sapiens (human)
G protein-coupled receptor activityExtracellular calcium-sensing receptorHomo sapiens (human)
integrin bindingExtracellular calcium-sensing receptorHomo sapiens (human)
calcium ion bindingExtracellular calcium-sensing receptorHomo sapiens (human)
protein bindingExtracellular calcium-sensing receptorHomo sapiens (human)
amino acid bindingExtracellular calcium-sensing receptorHomo sapiens (human)
protein kinase bindingExtracellular calcium-sensing receptorHomo sapiens (human)
protein homodimerization activityExtracellular calcium-sensing receptorHomo sapiens (human)
transmembrane transporter bindingExtracellular calcium-sensing receptorHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (41)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
external side of plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
membraneGlycine receptor subunit alpha-1Homo sapiens (human)
dendriteGlycine receptor subunit alpha-1Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-1Homo sapiens (human)
neuronal cell bodyGlycine receptor subunit alpha-1Homo sapiens (human)
perikaryonGlycine receptor subunit alpha-1Homo sapiens (human)
intracellular membrane-bounded organelleGlycine receptor subunit alpha-1Homo sapiens (human)
synapseGlycine receptor subunit alpha-1Homo sapiens (human)
postsynaptic membraneGlycine receptor subunit alpha-1Homo sapiens (human)
inhibitory synapseGlycine receptor subunit alpha-1Homo sapiens (human)
glycinergic synapseGlycine receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGlycine receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGlycine receptor subunit alpha-1Homo sapiens (human)
synapseGlycine receptor subunit alpha-1Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-1Homo sapiens (human)
plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
plasma membraneExtracellular calcium-sensing receptorHomo sapiens (human)
cell surfaceExtracellular calcium-sensing receptorHomo sapiens (human)
basolateral plasma membraneExtracellular calcium-sensing receptorHomo sapiens (human)
apical plasma membraneExtracellular calcium-sensing receptorHomo sapiens (human)
neuronal cell bodyExtracellular calcium-sensing receptorHomo sapiens (human)
axon terminusExtracellular calcium-sensing receptorHomo sapiens (human)
plasma membraneExtracellular calcium-sensing receptorHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (62)

Assay IDTitleYearJournalArticle
AID1808020Inhibition of porcine heart malate dehydrogenase preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1203551Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents at 10 uM after 1 to 4 days by two-electrode voltage clamp assay relative to control2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1808021Inhibition of porcine heart malate dehydrogenase assessed as reduction in enzyme inhibition at 3 times IC50 preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec in presence of 0.01% Triton-X100 by spectrop2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1808022Inhibition of porcine heart malate dehydrogenase assessed as critical aggregation concentration preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1203549Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents at 1 uM after 1 to 4 days by two-electrode voltage clamp assay relative to control2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1203552Modulation of human alpha7 nAChR expressed in Xenopus laevis oocytes assessed as effect on acetylcholine-induced currents at 10 uM after 1 to 4 days by two-electrode voltage clamp assay relative to control2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1203550Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents after 1 to 4 days by two-electrode voltage clamp assay2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID738057Positive allosteric modulation of human CaSR transfected in CHO cells after 5 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
New potent calcimimetics: I. Discovery of a series of novel trisubstituted ureas.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1808024Inhibition of recombinant human ACE2 using MCA-Tyr-Val-Ala-Asp-Ala-Pro-Lys(DNP)-OH as substrate preincubated for 15 mins followed by substrate addition and measured upto 15 mins by fluorescence assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346721Human CaS receptor (Calcium-sensing receptor)2013Endocrinology, Mar, Volume: 154, Issue:3
Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators.
AID1346721Human CaS receptor (Calcium-sensing receptor)2004The Journal of pharmacology and experimental therapeutics, Feb, Volume: 308, Issue:2
Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl.
AID1346721Human CaS receptor (Calcium-sensing receptor)2015British journal of pharmacology, Jan, Volume: 172, Issue:1
Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics.
AID1346721Human CaS receptor (Calcium-sensing receptor)2016Cell research, 05, Volume: 26, Issue:5
Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor.
AID1346721Human CaS receptor (Calcium-sensing receptor)2012Endocrinology, Mar, Volume: 153, Issue:3
Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (996)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's312 (31.33)29.6817
2010's555 (55.72)24.3611
2020's129 (12.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 87.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index87.38 (24.57)
Research Supply Index7.11 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index158.66 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (87.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials155 (14.49%)5.53%
Reviews229 (21.40%)6.00%
Case Studies162 (15.14%)4.05%
Observational36 (3.36%)0.25%
Other488 (45.61%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]